Y-mAbs Therapeutics, Inc. (10)

Browse by Contract Category

Contracts

License Agreement dated December 17, 2020 between Y-mabs Therapeutics, Inc., and SciClone Pharmaceuticals International Ltd (Filed With SEC on December 22, 2020)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, directors) (Filed With SEC on November 5, 2020)
Master Sponsored Research Agreement effective as of October 7, 2020 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on October 8, 2020)
Settlement and Assumption and Assignment of MSK License Agreement and Y-mAbs Sublicense Agreement, dated as of December 2, 2019, by and among the Company, MabVax Therapeutics... (Filed With SEC on December 19, 2019)
Underwriting Agreement, dated October 29, 2019, by and among the Company and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of... (Filed With SEC on October 31, 2019)
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan (as amended, employees, consultants and service providers other than directors) (Filed With SEC on November 5, 2020)
License Agreement, effective as of April 15, 2020, by and among the Company, Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology (Filed With SEC on April 21, 2020)
Description of the registrants securities registered pursuant to section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)
Y-mAbs Sublicense Agreement, dated as of June 27, 2018, by and between the Company and MabVax Therapeutics Holdings, Inc (Filed With SEC on December 19, 2019)
Amended and Restated Sponsored Research Agreement effective as of September 13, 2019 by and between the Company and Memorial Sloan Kettering Cancer Center (Filed With SEC on September 19, 2019)